Enfuvirtide
Also known as Fuzeon, T-20
One-dose burn-down
Half-life
3.8 h
Tmax
6.0 h
Bioavailability
84%
Typical dose
90 mg
HIV-1 fusion inhibitor peptide for treatment-experienced patients with resistant virus. Dosed 90 mg subcutaneously twice daily.
Mechanism of action
Binds gp41 to block the conformational change HIV-1 needs to fuse with and enter host cells.
Approved drug (Fuzeon). Injection-site reactions are common. Half-life ~3.8 h (twice-daily dosing).
Track Enfuvirtide for free
Log your doses and PeptideBuddy models Enfuvirtide's half-life into a live chart so you always know how much is active — plus reminders, reconstitution and protocol planning.
Start tracking free